Published in J Infect Dis on February 15, 2010
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J (2011) 5.65
The parasite clearance curve. Malar J (2011) 4.30
In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J (2012) 3.13
Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother (2012) 3.12
Malaria in the Greater Mekong Subregion: heterogeneity and complexity. Acta Trop (2011) 2.70
Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis (2016) 2.66
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis (2013) 2.47
Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One (2011) 2.33
Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One (2011) 2.00
Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg (2012) 1.97
No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg (2012) 1.87
Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis (2011) 1.68
The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med (2013) 1.64
Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet Infect Dis (2012) 1.53
Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis (2013) 1.52
Measuring the efficacy of anti-malarial drugs in vivo: quantitative PCR measurement of parasite clearance. Malar J (2010) 1.50
How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance? Antimicrob Agents Chemother (2015) 1.44
Drug-Resistant Malaria: The Era of ACT. Curr Infect Dis Rep (2010) 1.33
Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia. Malar J (2013) 1.27
Evidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to artemether. Mem Inst Oswaldo Cruz (2013) 1.25
Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J (2014) 1.24
Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives. Malar J (2013) 1.21
Current status of artemisinin-resistant falciparum malaria in South Asia: a randomized controlled artesunate monotherapy trial in Bangladesh. PLoS One (2012) 1.19
Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread. Int J Antimicrob Agents (2013) 1.19
No evidence for spread of Plasmodium falciparum artemisinin resistance to Savannakhet Province, Southern Laos. Am J Trop Med Hyg (2012) 1.16
Early parasitological response following artemisinin-containing regimens: a critical review of the literature. Malar J (2013) 1.14
Artemisinin Resistance at the China-Myanmar Border and Association with Mutations in the K13 Propeller Gene. Antimicrob Agents Chemother (2015) 1.13
Clinical Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria at the China-Myanmar Border. Am J Trop Med Hyg (2015) 1.05
In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia. Malar J (2011) 1.03
The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev (2016) 0.99
Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malar J (2016) 0.99
Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999-2009. Malar J (2014) 0.98
Genetic evaluation of the performance of malaria parasite clearance rate metrics. J Infect Dis (2013) 0.94
Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia. Malar J (2012) 0.94
Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments. Am J Trop Med Hyg (2011) 0.94
Antimalarial exposure delays Plasmodium falciparum intra-erythrocytic cycle and drives drug transporter genes expression. PLoS One (2010) 0.93
Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children. Am J Trop Med Hyg (2014) 0.93
Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. PLoS Med (2015) 0.90
Efficacy and effectiveness of mefloquine and artesunate combination therapy for uncomplicated Plasmodium falciparum malaria in the Peruvian Amazon. Am J Trop Med Hyg (2011) 0.89
More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effects. PLoS Negl Trop Dis (2012) 0.86
Rapid response to selection, competitive release and increased transmission potential of artesunate-selected Plasmodium chabaudi malaria parasites. PLoS Pathog (2014) 0.84
Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia. Antimicrob Agents Chemother (2016) 0.83
Understanding genetic variation in in vivo tolerance to artesunate: implications for treatment efficacy and resistance monitoring. Evol Appl (2014) 0.83
Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. Genome Biol (2017) 0.82
Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya. Int J Parasitol Drugs Drug Resist (2015) 0.80
Atypical mitogen-activated protein kinase phosphatase implicated in regulating transition from pre-S-Phase asexual intraerythrocytic development of Plasmodium falciparum. Eukaryot Cell (2013) 0.80
Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model. Antimicrob Agents Chemother (2013) 0.79
US Department of Defense contributions to malaria surveillance. Lancet Infect Dis (2013) 0.79
No evidence of decreased artemisinin efficacy in a high-transmission malaria setting in Mali. Am J Trop Med Hyg (2012) 0.78
Risk factors for Plasmodium falciparum hyperparasitaemia in malarious children. BMC Infect Dis (2011) 0.78
Analysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIX™). Malar J (2015) 0.78
Assessing parasite clearance during uncomplicated Plasmodium falciparum infection treated with artesunate monotherapy in Suriname. Infect Drug Resist (2016) 0.78
Delayed Plasmodium falciparum clearance following artesunate-mefloquine combination therapy in Thailand, 1997-2007. Malar J (2012) 0.77
Altered drug susceptibility during host adaptation of a Plasmodium falciparum strain in a non-human primate model. Sci Rep (2016) 0.76
In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine in Mali. Am J Trop Med Hyg (2016) 0.75
Efficacy of Chloroquine for the Treatment of Vivax malaria in Northwest Ethiopia. PLoS One (2016) 0.75
Genetically Determined Response to Artemisinin Treatment in Western Kenyan Plasmodium falciparum Parasites. PLoS One (2016) 0.75
Immunity as a predictor of anti-malarial treatment failure: a systematic review. Malar J (2017) 0.75
Malaria parasite clearance. Malar J (2017) 0.75
Early rising asexual parasitaemia in Nigerian children following a first dose of artemisinin-based combination treatments of falciparum malaria. BMC Infect Dis (2017) 0.75
Split dosing of artemisinins does not improve antimalarial therapeutic efficacy. Sci Rep (2017) 0.75
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med (1998) 20.81
Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med (2008) 17.65
Intercontinental spread of pyrimethamine-resistant malaria. Science (2004) 8.73
Antimalarial drug resistance. J Clin Invest (2004) 8.50
Qinghaosu (artemisinin): the price of success. Science (2008) 8.25
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother (1997) 7.36
Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 7.06
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol (1993) 4.98
Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis (2008) 4.68
Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg (2007) 4.51
Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health (2006) 4.44
Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health (2006) 4.32
Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis (1994) 4.17
Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. J Trop Med Hyg (1986) 3.34
Central role of the spleen in malaria parasite clearance. J Infect Dis (2002) 2.80
Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis (1996) 2.59
The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis (2000) 2.35
Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg (1996) 2.24
Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg (1994) 2.22
High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis (1992) 2.21
Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood (1996) 2.01
In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasitol (1996) 1.90
Chloroquine-resistant falciparum malaria in Thailand. Lancet (1965) 1.89
In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood (1997) 1.85
World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J (2007) 1.56
The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria. Malar J (2008) 1.29
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
The B73 maize genome: complexity, diversity, and dynamics. Science (2009) 18.73
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet (2005) 12.98
Typhoid fever. N Engl J Med (2002) 12.96
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet (2002) 11.72
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis (2007) 10.66
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med (2004) 10.14
WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet (2004) 9.27
Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci U S A (2004) 8.95
Intercontinental spread of pyrimethamine-resistant malaria. Science (2004) 8.73
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med (2005) 8.36
How clonal is Staphylococcus aureus? J Bacteriol (2003) 7.97
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
Reduced efficacy of insecticide-treated nets and indoor residual spraying for malaria control in pyrethroid resistance area, Benin. Emerg Infect Dis (2007) 6.84
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol (2006) 6.34
Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol (2010) 6.28
A major genome region underlying artemisinin resistance in malaria. Science (2012) 6.25
Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis (2013) 6.06
Seven years of regional malaria control collaboration--Mozambique, South Africa, and Swaziland. Am J Trop Med Hyg (2007) 6.04
Mixed-species malaria infections in humans. Trends Parasitol (2004) 6.01
Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg (2006) 5.91
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J (2011) 5.65
The murine cerebral malaria phenomenon. Trends Parasitol (2009) 5.62
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis (2005) 5.58
A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis (2012) 5.24
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg (2010) 5.10
What errors do peer reviewers detect, and does training improve their ability to detect them? J R Soc Med (2008) 4.92
Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis (2012) 4.84
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med (2005) 4.65
Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun (2002) 4.62
Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda. J Infect Dis (2008) 4.60
Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg (2007) 4.58
The pathophysiology of vivax malaria. Trends Parasitol (2009) 4.57
Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (2010) 4.50
Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med (2005) 4.47
Manslaughter by fake artesunate in Asia--will Africa be next? PLoS Med (2006) 4.46
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
How to achieve international action on falsified and substandard medicines. BMJ (2012) 4.36
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis (2007) 4.35
Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J (2008) 4.33
The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J (2009) 4.25
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis (2006) 4.14
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (2004) 4.14
Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries. Cochrane Database Syst Rev (2011) 4.11
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A (2012) 4.10
Early origin and recent expansion of Plasmodium falciparum. Science (2003) 4.07
Treatment of malaria restricted to laboratory-confirmed cases: a prospective cohort study in Ugandan children. Malar J (2007) 4.05
The Innovative Vector Control Consortium: improved control of mosquito-borne diseases. Trends Parasitol (2006) 4.04
Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet (2007) 3.93
Counterfeit anti-infective drugs. Lancet Infect Dis (2006) 3.91
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet (2006) 3.90
Rickettsial infections and fever, Vientiane, Laos. Emerg Infect Dis (2006) 3.87
Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLoS Med (2006) 3.83
High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis (2010) 3.81
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (2004) 3.72
Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg (2003) 3.71